Albert Coo, MD
Endocrinology, Diabetes & Metabolism · Alexandria, VANPI 1336160837
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,365 of the $16,818 with a category attached, or 79.5%. 58 manufacturers reported payments, led by Corcept Therapeutics at 27.6% of the total. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 710 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$5K
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$1K
- AbbVie$845
- Xeris Pharmaceuticals, Inc.$843
- plus $6K from 52 others
What the payments were for
- Consulting fees$2,25013%
- Speaking & faculty fees$8755%
- Food & beverage$13,36579%
- Education$2692%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,818 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 17 | $655,398 |
| OzempicSemaglutide | 114 | $230,673 |
| JardianceEmpagliflozin | 137 | $197,194 |
| TrulicityDulaglutide | 111 | $172,363 |
| RybelsusSemaglutide | 51 | $124,018 |
| FarxigaDapagliflozin Propanediol | 87 | $110,683 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $69,612 |
| JanuviaSitagliptin Phosphate | 42 | $62,901 |
| MounjaroTirzepatide | 25 | $42,413 |
| GenotropinSomatropin | 13 | $38,479 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $36,785 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $28,527 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $22,866 |
| EliquisApixaban | 17 | $22,120 |
| SynthroidLevothyroxine Sodium | 254 | $20,557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $4,640 | $655,39817 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $1,333 | $358,488176 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,807 | $222,485169 claims |
| Boehringer IngelheimJardiance | $249 | $197,194137 claims |
| AstraZenecaFarxiga | $325 | $110,68387 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,086 | $69,61247 claims |
| MerckJanuvia | $384 | $62,90142 claims |
| PfizerGenotropin, Eliquis | $64 | $60,59930 claims |
| AbbVieSynthroid, Armour Thyroid | $845 | $23,450280 claims |
| BayerKerendia | $421 | $19,58314 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $11,00411 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $565 | $4,566341 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Alexandria
- Aytan MammadovaAlexandria$8K
- Anuradha DuaAlexandria$5K
- Howard LandoAlexandria$4K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.